论文部分内容阅读
血小板和纤溶血凝系统的功能亢进是脑栓塞的危险因子。本文选择30例脑血管障碍病例和9例包括高脂血症、高血压、糖尿病病例给于马来酸氢化麦角乙脲(Lisuride hydrogen maleate,国外商品名Eunal,以下称Eunal)治疗,同时测定血小板聚集试验。治疗和测定方法 Eunal每日3次,每片含马来酸氢化麦角乙脲0.05mg。用药前、用药后4周、用药后8周测定血小板聚集试验。35例血小板聚集测试方法用吸光度法,4例用筛孔滤过压法(Screen Filtration Pressure)。共用三组药物作致聚剂诱导血小板聚集。第一组AOP用量为0.5
Platelet and fibrinolytic coagulation system hyperthyroidism is a risk factor for cerebral embolism. In this paper, 30 cases of cerebrovascular disease and 9 cases including hyperlipidemia, hypertension and diabetes mellitus were treated with Lisuride hydrogen maleate (Eunal, a foreign trade name), meanwhile platelet Aggregation test. Treatment and Assay Methods Eunal 3 times daily, each containing 0.05 mg of hydrogenated lisuronic acid maleate. Before treatment, 4 weeks after treatment, platelet aggregation test was performed 8 weeks after treatment. 35 cases of platelet aggregation test by absorbance method, 4 cases by mesh filtration method (Screen Filtration Pressure). Common three groups of drugs for polymerization agent induced platelet aggregation. The first AOP usage is 0.5